Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIC immunosuppression versus standard of care in living donor kidney transplantation
2024-513446-12-00Phase 2Authorised
- Sponsor
- TolerogenixX
- Start
- May 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MIC-Tx in kidney failure and chronic kidney disease (CKD) (3 arms), sponsored by TolerogenixX. Primary endpoint: Operational tolerance-like phenotype at Day 367. Planned start May 2022; status: authorised.
02
Drugs
MIC-Tx
03
Conditions
kidney failurechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-513446-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513446-12-00.